Marion Trautmann - Academia.edu (original) (raw)

Uploads

Papers by Marion Trautmann

Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but i... more Pseudomonas aeruginosa is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease. This study analyzed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of P. aeruginosa chronic infection and its independent impact on exacerbations, hospitalizations, quality of life and mortality was assessed. The prevalence of P. aeruginosa chronic infection was 15.0% (n=389). P.aeruginosa was associated with a higher mortality in a univariate analysis (HR: 2.02; 95% CI 1.53– 2.66;p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR: 0.98; 95% CI 0.70–1.36;p=0.89). P. aeruginosa was independently associated with increased mortality only in patients with frequent exacerbations (2 or more per year) (HR 2.03; 95...

European Respiratory Journal, 2018

$Research paper thumbnail of {"__content__"=>"The independent contribution of infection to long-term clinical outcomes in bronchiectasis.", "i"=>{"__content__"=>"Pseudomonas aeruginosa"}}$

The European respiratory journal, Feb 1, 2018

is responsible for chronic infection in many bronchiectasis patients but it is not known whether ... more is responsible for chronic infection in many bronchiectasis patients but it is not known whether it is associated with worse clinical outcomes independent of the underlying severity of disease.This study analysed data from 2596 bronchiectasis patients included from 10 different bronchiectasis clinical centres across Europe and Israel, with a 5-year follow-up period. Prevalence of chronic infection and its independent impact on exacerbations, hospitalisations, quality of life and mortality was assessed.The prevalence of chronic infection was 15.0% (n=389). was associated with a higher mortality in a univariate analysis (hazard ratio (HR) 2.02; 95% (confidence interval) CI 1.53-2.66; p<0.0001) but an independent impact on mortality was not found in a multivariate analysis (HR 0.98; 95% CI 0.70-1.36; p=0.89). was independently associated with increased mortality only in patients with frequent exacerbations (two or more per year) (HR 2.03; 95% CI 1.36-3.03; p=0.001). An independent a...

European Journal of Pharmacology, 1991

The effect of oral administration of various non-steroidal antiin~ammato~ drugs on ethanol-induce... more The effect of oral administration of various non-steroidal antiin~ammato~ drugs on ethanol-induced rat gastric injury and mucosal release of leukotriene Cq, 6-ket~prostaglandin F,, and IS-hydroxy-5,8,11,13-eicosatetraenoic acid was investigated. It was found that besides sodium salicyiate and high doses of aspirin, other salicylate-type drugs, such as difiunisal, 4-aminosalicylic acid, 2,4-dihydroxybenzoic acid and methyl salieylate, and several non-acidic compounds, such as proquazone, benzydamine and paracetamol, were gastroprotective. All these drugs inhibited ex vivo leukotrienc C., formation by ethanol-stimulated gastric mucosa. However, naproxen, lonazolac, ibuprofen, Fentisic acid and 5-aminosalicylic acid also inhibited leukotriene C4 fo~ation, but were not protective. Gastroprotection was independent of 6-keto-pros~ag~andin F,, formation. Both protective and non-protective drugs inhibited the ethanol-stimulated, but not the basal, release of 15-hydroxy-5,8.11,13-eicosa~~tracnoi~ acid. The results indicate that the differential effects of various non-steroidal antiinflammatory drugs on gastroprotection against ethanol are not correlated with specific effects on mucosal cyclooxygcnase, Nipoxygenase or lS-lipoxygenase activity.

Clinical Drug Investigation, 1998

Objective: The objective of this study was to assess the relative cost effectiveness of fluticaso... more Objective: The objective of this study was to assess the relative cost effectiveness of fluticasone via metered dose inhaler and budesonide via Turbuhaler ® in corticosteroid-naive patients with moderate asthma from a third-party payer perspective (German Sickness Funds). Patients and Methods: A retrospective economic assessment of direct medication costs of treatment was performed on data from a prospective, randomised, parallel group, 6-week clinical trial. 457 corticosteroid-naive patients between the ages of 18 and 70 years with moderate asthma were included in the intentionto-treat analysis. Results: The fluticasone group had a higher proportion of successfully treated patients (those with a peak expiratory flow rate improvement of ≥10%) [47 vs 42%], a higher average proportion of symptom-free days (40 vs 34%) and lower direct healthcare costs [1997 Deutschmarks (DM)] per day (DM4.23 vs DM5.19) than the budesonide group. Therefore, the daily costs per successfully treated patient (DM9.00 vs DM12.36) and the cost per symptom-free day (DM10.58 vs DM15.26) were both lower with fluticasone than with budesonide. Sensitivity analysis demonstrated that these results were relatively robust over a wide range of plausible assumptions. Conclusion: These results showed that from the perspective of a third-party payer, fluticasone was more cost effective than budesonide over the 6-week study period.

Clinical Drug Investigation, Aug 28, 2012

Clin Drug Invest, 1998